nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Carmustine—melanoma	0.28	0.417	CbGbCtD
Anagrelide—CYP1A2—Vemurafenib—melanoma	0.221	0.33	CbGbCtD
Anagrelide—CYP1A2—Dacarbazine—melanoma	0.169	0.253	CbGbCtD
Anagrelide—Renal impairment—Docetaxel—melanoma	0.000781	0.00252	CcSEcCtD
Anagrelide—Haemoglobin—Temozolomide—melanoma	0.000777	0.00251	CcSEcCtD
Anagrelide—Haemorrhage—Temozolomide—melanoma	0.000773	0.00249	CcSEcCtD
Anagrelide—Hepatitis—Temozolomide—melanoma	0.000773	0.00249	CcSEcCtD
Anagrelide—Asthenia—Vemurafenib—melanoma	0.000771	0.00249	CcSEcCtD
Anagrelide—Visual impairment—Carmustine—melanoma	0.000771	0.00249	CcSEcCtD
Anagrelide—Hypoaesthesia—Temozolomide—melanoma	0.00077	0.00248	CcSEcCtD
Anagrelide—Pharyngitis—Temozolomide—melanoma	0.000768	0.00247	CcSEcCtD
Anagrelide—Chills—Dactinomycin—melanoma	0.000767	0.00247	CcSEcCtD
Anagrelide—Urinary tract disorder—Temozolomide—melanoma	0.000764	0.00246	CcSEcCtD
Anagrelide—Oedema peripheral—Temozolomide—melanoma	0.000762	0.00246	CcSEcCtD
Anagrelide—Cardiac failure—Docetaxel—melanoma	0.000762	0.00246	CcSEcCtD
Anagrelide—Pruritus—Vemurafenib—melanoma	0.000761	0.00245	CcSEcCtD
Anagrelide—Connective tissue disorder—Temozolomide—melanoma	0.00076	0.00245	CcSEcCtD
Anagrelide—Urethral disorder—Temozolomide—melanoma	0.000758	0.00244	CcSEcCtD
Anagrelide—Alopecia—Dactinomycin—melanoma	0.000756	0.00244	CcSEcCtD
Anagrelide—Eye disorder—Carmustine—melanoma	0.000748	0.00241	CcSEcCtD
Anagrelide—Visual impairment—Temozolomide—melanoma	0.000745	0.0024	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000743	0.0024	CcSEcCtD
Anagrelide—Ill-defined disorder—Bleomycin—melanoma	0.000741	0.00239	CcSEcCtD
Anagrelide—Anaemia—Bleomycin—melanoma	0.000738	0.00238	CcSEcCtD
Anagrelide—Diarrhoea—Vemurafenib—melanoma	0.000736	0.00237	CcSEcCtD
Anagrelide—Migraine—Docetaxel—melanoma	0.000732	0.00236	CcSEcCtD
Anagrelide—Eye disorder—Temozolomide—melanoma	0.000723	0.00233	CcSEcCtD
Anagrelide—Tinnitus—Temozolomide—melanoma	0.000721	0.00232	CcSEcCtD
Anagrelide—Malaise—Bleomycin—melanoma	0.00072	0.00232	CcSEcCtD
Anagrelide—Cardiac disorder—Temozolomide—melanoma	0.000718	0.00231	CcSEcCtD
Anagrelide—Arrhythmia—Carmustine—melanoma	0.000715	0.0023	CcSEcCtD
Anagrelide—Dizziness—Vemurafenib—melanoma	0.000711	0.00229	CcSEcCtD
Anagrelide—Alopecia—Carmustine—melanoma	0.000707	0.00228	CcSEcCtD
Anagrelide—Mediastinal disorder—Temozolomide—melanoma	0.000697	0.00225	CcSEcCtD
Anagrelide—Malnutrition—Carmustine—melanoma	0.000697	0.00225	CcSEcCtD
Anagrelide—Cough—Bleomycin—melanoma	0.000696	0.00224	CcSEcCtD
Anagrelide—Chills—Temozolomide—melanoma	0.000694	0.00224	CcSEcCtD
Anagrelide—Dehydration—Docetaxel—melanoma	0.000691	0.00223	CcSEcCtD
Anagrelide—Ill-defined disorder—Dactinomycin—melanoma	0.000691	0.00223	CcSEcCtD
Anagrelide—Anaemia—Dactinomycin—melanoma	0.000688	0.00222	CcSEcCtD
Anagrelide—Liver function test abnormal—Docetaxel—melanoma	0.000686	0.00221	CcSEcCtD
Anagrelide—Vomiting—Vemurafenib—melanoma	0.000684	0.0022	CcSEcCtD
Anagrelide—Alopecia—Temozolomide—melanoma	0.000683	0.0022	CcSEcCtD
Anagrelide—Dry skin—Docetaxel—melanoma	0.000681	0.0022	CcSEcCtD
Anagrelide—Myalgia—Bleomycin—melanoma	0.00068	0.00219	CcSEcCtD
Anagrelide—Chest pain—Bleomycin—melanoma	0.00068	0.00219	CcSEcCtD
Anagrelide—Orthostatic hypotension—Docetaxel—melanoma	0.000679	0.00219	CcSEcCtD
Anagrelide—Rash—Vemurafenib—melanoma	0.000678	0.00218	CcSEcCtD
Anagrelide—Dermatitis—Vemurafenib—melanoma	0.000677	0.00218	CcSEcCtD
Anagrelide—Back pain—Carmustine—melanoma	0.000674	0.00217	CcSEcCtD
Anagrelide—Headache—Vemurafenib—melanoma	0.000674	0.00217	CcSEcCtD
Anagrelide—Malnutrition—Temozolomide—melanoma	0.000673	0.00217	CcSEcCtD
Anagrelide—Discomfort—Bleomycin—melanoma	0.000671	0.00216	CcSEcCtD
Anagrelide—Malaise—Dactinomycin—melanoma	0.000671	0.00216	CcSEcCtD
Anagrelide—Confusional state—Bleomycin—melanoma	0.000657	0.00212	CcSEcCtD
Anagrelide—Vision blurred—Carmustine—melanoma	0.000657	0.00212	CcSEcCtD
Anagrelide—Oedema—Bleomycin—melanoma	0.000651	0.0021	CcSEcCtD
Anagrelide—Back pain—Temozolomide—melanoma	0.000651	0.0021	CcSEcCtD
Anagrelide—Infection—Bleomycin—melanoma	0.000647	0.00209	CcSEcCtD
Anagrelide—Anaemia—Carmustine—melanoma	0.000644	0.00208	CcSEcCtD
Anagrelide—Dysphagia—Docetaxel—melanoma	0.000643	0.00207	CcSEcCtD
Anagrelide—Nausea—Vemurafenib—melanoma	0.000639	0.00206	CcSEcCtD
Anagrelide—Thrombocytopenia—Bleomycin—melanoma	0.000638	0.00206	CcSEcCtD
Anagrelide—Vision blurred—Temozolomide—melanoma	0.000635	0.00205	CcSEcCtD
Anagrelide—Myalgia—Dactinomycin—melanoma	0.000634	0.00204	CcSEcCtD
Anagrelide—Discomfort—Dactinomycin—melanoma	0.000626	0.00202	CcSEcCtD
Anagrelide—Angina pectoris—Docetaxel—melanoma	0.000626	0.00202	CcSEcCtD
Anagrelide—Ill-defined disorder—Temozolomide—melanoma	0.000625	0.00201	CcSEcCtD
Anagrelide—Anaemia—Temozolomide—melanoma	0.000622	0.00201	CcSEcCtD
Anagrelide—Anorexia—Bleomycin—melanoma	0.000621	0.002	CcSEcCtD
Anagrelide—Pancytopenia—Docetaxel—melanoma	0.00061	0.00197	CcSEcCtD
Anagrelide—Hypotension—Bleomycin—melanoma	0.000609	0.00196	CcSEcCtD
Anagrelide—Oedema—Dactinomycin—melanoma	0.000608	0.00196	CcSEcCtD
Anagrelide—Malaise—Temozolomide—melanoma	0.000607	0.00196	CcSEcCtD
Anagrelide—Convulsion—Carmustine—melanoma	0.000604	0.00195	CcSEcCtD
Anagrelide—Infection—Dactinomycin—melanoma	0.000604	0.00195	CcSEcCtD
Anagrelide—Hypertension—Carmustine—melanoma	0.000601	0.00194	CcSEcCtD
Anagrelide—Palpitations—Temozolomide—melanoma	0.000595	0.00192	CcSEcCtD
Anagrelide—Thrombocytopenia—Dactinomycin—melanoma	0.000595	0.00192	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Bleomycin—melanoma	0.000593	0.00191	CcSEcCtD
Anagrelide—Chest pain—Carmustine—melanoma	0.000593	0.00191	CcSEcCtD
Anagrelide—Myalgia—Carmustine—melanoma	0.000593	0.00191	CcSEcCtD
Anagrelide—Cough—Temozolomide—melanoma	0.000588	0.00189	CcSEcCtD
Anagrelide—Paraesthesia—Bleomycin—melanoma	0.000585	0.00189	CcSEcCtD
Anagrelide—Weight increased—Docetaxel—melanoma	0.000585	0.00188	CcSEcCtD
Anagrelide—Convulsion—Temozolomide—melanoma	0.000583	0.00188	CcSEcCtD
Anagrelide—Weight decreased—Docetaxel—melanoma	0.000581	0.00187	CcSEcCtD
Anagrelide—Hypertension—Temozolomide—melanoma	0.000581	0.00187	CcSEcCtD
Anagrelide—Dyspnoea—Bleomycin—melanoma	0.000581	0.00187	CcSEcCtD
Anagrelide—Anorexia—Dactinomycin—melanoma	0.000579	0.00187	CcSEcCtD
Anagrelide—Pneumonia—Docetaxel—melanoma	0.000576	0.00186	CcSEcCtD
Anagrelide—Confusional state—Carmustine—melanoma	0.000573	0.00185	CcSEcCtD
Anagrelide—Arthralgia—Temozolomide—melanoma	0.000573	0.00185	CcSEcCtD
Anagrelide—Myalgia—Temozolomide—melanoma	0.000573	0.00185	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000569	0.00183	CcSEcCtD
Anagrelide—Oedema—Carmustine—melanoma	0.000569	0.00183	CcSEcCtD
Anagrelide—Discomfort—Temozolomide—melanoma	0.000566	0.00183	CcSEcCtD
Anagrelide—Decreased appetite—Bleomycin—melanoma	0.000566	0.00183	CcSEcCtD
Anagrelide—Infection—Carmustine—melanoma	0.000565	0.00182	CcSEcCtD
Anagrelide—Acute coronary syndrome—Docetaxel—melanoma	0.000565	0.00182	CcSEcCtD
Anagrelide—Renal failure—Docetaxel—melanoma	0.000563	0.00182	CcSEcCtD
Anagrelide—Myocardial infarction—Docetaxel—melanoma	0.000562	0.00181	CcSEcCtD
Anagrelide—Dry mouth—Temozolomide—melanoma	0.000561	0.00181	CcSEcCtD
Anagrelide—Pain—Bleomycin—melanoma	0.000557	0.0018	CcSEcCtD
Anagrelide—Conjunctivitis—Docetaxel—melanoma	0.000557	0.00179	CcSEcCtD
Anagrelide—Thrombocytopenia—Carmustine—melanoma	0.000557	0.00179	CcSEcCtD
Anagrelide—Tachycardia—Carmustine—melanoma	0.000555	0.00179	CcSEcCtD
Anagrelide—Confusional state—Temozolomide—melanoma	0.000554	0.00179	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000553	0.00178	CcSEcCtD
Anagrelide—Oedema—Temozolomide—melanoma	0.000549	0.00177	CcSEcCtD
Anagrelide—Infection—Temozolomide—melanoma	0.000546	0.00176	CcSEcCtD
Anagrelide—Anorexia—Carmustine—melanoma	0.000542	0.00175	CcSEcCtD
Anagrelide—Hepatobiliary disease—Docetaxel—melanoma	0.000542	0.00175	CcSEcCtD
Anagrelide—Epistaxis—Docetaxel—melanoma	0.00054	0.00174	CcSEcCtD
Anagrelide—Nervous system disorder—Temozolomide—melanoma	0.000539	0.00174	CcSEcCtD
Anagrelide—Thrombocytopenia—Temozolomide—melanoma	0.000538	0.00173	CcSEcCtD
Anagrelide—Feeling abnormal—Bleomycin—melanoma	0.000537	0.00173	CcSEcCtD
Anagrelide—Skin disorder—Temozolomide—melanoma	0.000534	0.00172	CcSEcCtD
Anagrelide—Hypotension—Carmustine—melanoma	0.000531	0.00171	CcSEcCtD
Anagrelide—Hyperhidrosis—Temozolomide—melanoma	0.000531	0.00171	CcSEcCtD
Anagrelide—Decreased appetite—Dactinomycin—melanoma	0.000528	0.0017	CcSEcCtD
Anagrelide—Fatigue—Dactinomycin—melanoma	0.000524	0.00169	CcSEcCtD
Anagrelide—Anorexia—Temozolomide—melanoma	0.000524	0.00169	CcSEcCtD
Anagrelide—Pain—Dactinomycin—melanoma	0.00052	0.00167	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Carmustine—melanoma	0.000518	0.00167	CcSEcCtD
Anagrelide—Urticaria—Bleomycin—melanoma	0.000517	0.00167	CcSEcCtD
Anagrelide—Haemoglobin—Docetaxel—melanoma	0.000517	0.00167	CcSEcCtD
Anagrelide—Rhinitis—Docetaxel—melanoma	0.000516	0.00166	CcSEcCtD
Anagrelide—Body temperature increased—Bleomycin—melanoma	0.000515	0.00166	CcSEcCtD
Anagrelide—Haemorrhage—Docetaxel—melanoma	0.000514	0.00166	CcSEcCtD
Anagrelide—Hepatitis—Docetaxel—melanoma	0.000514	0.00166	CcSEcCtD
Anagrelide—Insomnia—Carmustine—melanoma	0.000514	0.00166	CcSEcCtD
Anagrelide—Hypoaesthesia—Docetaxel—melanoma	0.000512	0.00165	CcSEcCtD
Anagrelide—Paraesthesia—Carmustine—melanoma	0.000511	0.00165	CcSEcCtD
Anagrelide—Pharyngitis—Docetaxel—melanoma	0.00051	0.00165	CcSEcCtD
Anagrelide—Urinary tract disorder—Docetaxel—melanoma	0.000508	0.00164	CcSEcCtD
Anagrelide—Dyspnoea—Carmustine—melanoma	0.000507	0.00163	CcSEcCtD
Anagrelide—Oedema peripheral—Docetaxel—melanoma	0.000507	0.00163	CcSEcCtD
Anagrelide—Somnolence—Carmustine—melanoma	0.000505	0.00163	CcSEcCtD
Anagrelide—Connective tissue disorder—Docetaxel—melanoma	0.000505	0.00163	CcSEcCtD
Anagrelide—Urethral disorder—Docetaxel—melanoma	0.000504	0.00162	CcSEcCtD
Anagrelide—Feeling abnormal—Dactinomycin—melanoma	0.000501	0.00161	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Temozolomide—melanoma	0.000501	0.00161	CcSEcCtD
Anagrelide—Insomnia—Temozolomide—melanoma	0.000497	0.0016	CcSEcCtD
Anagrelide—Gastrointestinal pain—Dactinomycin—melanoma	0.000497	0.0016	CcSEcCtD
Anagrelide—Visual impairment—Docetaxel—melanoma	0.000496	0.0016	CcSEcCtD
Anagrelide—Decreased appetite—Carmustine—melanoma	0.000494	0.00159	CcSEcCtD
Anagrelide—Paraesthesia—Temozolomide—melanoma	0.000493	0.00159	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Carmustine—melanoma	0.000491	0.00158	CcSEcCtD
Anagrelide—Dyspnoea—Temozolomide—melanoma	0.00049	0.00158	CcSEcCtD
Anagrelide—Somnolence—Temozolomide—melanoma	0.000488	0.00157	CcSEcCtD
Anagrelide—Pain—Carmustine—melanoma	0.000486	0.00157	CcSEcCtD
Anagrelide—Constipation—Carmustine—melanoma	0.000486	0.00157	CcSEcCtD
Anagrelide—Dyspepsia—Temozolomide—melanoma	0.000484	0.00156	CcSEcCtD
Anagrelide—Eye disorder—Docetaxel—melanoma	0.000481	0.00155	CcSEcCtD
Anagrelide—Abdominal pain—Dactinomycin—melanoma	0.00048	0.00155	CcSEcCtD
Anagrelide—Body temperature increased—Dactinomycin—melanoma	0.00048	0.00155	CcSEcCtD
Anagrelide—Decreased appetite—Temozolomide—melanoma	0.000478	0.00154	CcSEcCtD
Anagrelide—Cardiac disorder—Docetaxel—melanoma	0.000477	0.00154	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Temozolomide—melanoma	0.000474	0.00153	CcSEcCtD
Anagrelide—Fatigue—Temozolomide—melanoma	0.000474	0.00153	CcSEcCtD
Anagrelide—Constipation—Temozolomide—melanoma	0.00047	0.00151	CcSEcCtD
Anagrelide—Pain—Temozolomide—melanoma	0.00047	0.00151	CcSEcCtD
Anagrelide—Feeling abnormal—Carmustine—melanoma	0.000469	0.00151	CcSEcCtD
Anagrelide—Asthenia—Bleomycin—melanoma	0.000467	0.00151	CcSEcCtD
Anagrelide—Gastrointestinal pain—Carmustine—melanoma	0.000465	0.0015	CcSEcCtD
Anagrelide—Mediastinal disorder—Docetaxel—melanoma	0.000464	0.00149	CcSEcCtD
Anagrelide—Chills—Docetaxel—melanoma	0.000461	0.00149	CcSEcCtD
Anagrelide—Pruritus—Bleomycin—melanoma	0.000461	0.00149	CcSEcCtD
Anagrelide—Arrhythmia—Docetaxel—melanoma	0.000459	0.00148	CcSEcCtD
Anagrelide—Alopecia—Docetaxel—melanoma	0.000454	0.00146	CcSEcCtD
Anagrelide—Feeling abnormal—Temozolomide—melanoma	0.000453	0.00146	CcSEcCtD
Anagrelide—Abdominal pain—Carmustine—melanoma	0.000449	0.00145	CcSEcCtD
Anagrelide—Body temperature increased—Carmustine—melanoma	0.000449	0.00145	CcSEcCtD
Anagrelide—Gastrointestinal pain—Temozolomide—melanoma	0.000449	0.00145	CcSEcCtD
Anagrelide—Malnutrition—Docetaxel—melanoma	0.000448	0.00144	CcSEcCtD
Anagrelide—Urticaria—Temozolomide—melanoma	0.000437	0.00141	CcSEcCtD
Anagrelide—Asthenia—Dactinomycin—melanoma	0.000436	0.0014	CcSEcCtD
Anagrelide—Abdominal pain—Temozolomide—melanoma	0.000434	0.0014	CcSEcCtD
Anagrelide—Body temperature increased—Temozolomide—melanoma	0.000434	0.0014	CcSEcCtD
Anagrelide—Back pain—Docetaxel—melanoma	0.000433	0.0014	CcSEcCtD
Anagrelide—Muscle spasms—Docetaxel—melanoma	0.00043	0.00139	CcSEcCtD
Anagrelide—Diarrhoea—Dactinomycin—melanoma	0.000416	0.00134	CcSEcCtD
Anagrelide—Vomiting—Bleomycin—melanoma	0.000414	0.00133	CcSEcCtD
Anagrelide—Anaemia—Docetaxel—melanoma	0.000414	0.00133	CcSEcCtD
Anagrelide—Rash—Bleomycin—melanoma	0.000411	0.00132	CcSEcCtD
Anagrelide—Dermatitis—Bleomycin—melanoma	0.00041	0.00132	CcSEcCtD
Anagrelide—Asthenia—Carmustine—melanoma	0.000408	0.00131	CcSEcCtD
Anagrelide—Syncope—Docetaxel—melanoma	0.000402	0.00129	CcSEcCtD
Anagrelide—Palpitations—Docetaxel—melanoma	0.000396	0.00128	CcSEcCtD
Anagrelide—Asthenia—Temozolomide—melanoma	0.000394	0.00127	CcSEcCtD
Anagrelide—Loss of consciousness—Docetaxel—melanoma	0.000394	0.00127	CcSEcCtD
Anagrelide—Cough—Docetaxel—melanoma	0.000391	0.00126	CcSEcCtD
Anagrelide—Diarrhoea—Carmustine—melanoma	0.000389	0.00125	CcSEcCtD
Anagrelide—Pruritus—Temozolomide—melanoma	0.000389	0.00125	CcSEcCtD
Anagrelide—Convulsion—Docetaxel—melanoma	0.000388	0.00125	CcSEcCtD
Anagrelide—Nausea—Bleomycin—melanoma	0.000387	0.00125	CcSEcCtD
Anagrelide—Hypertension—Docetaxel—melanoma	0.000387	0.00125	CcSEcCtD
Anagrelide—Vomiting—Dactinomycin—melanoma	0.000386	0.00124	CcSEcCtD
Anagrelide—Rash—Dactinomycin—melanoma	0.000383	0.00123	CcSEcCtD
Anagrelide—Chest pain—Docetaxel—melanoma	0.000381	0.00123	CcSEcCtD
Anagrelide—Myalgia—Docetaxel—melanoma	0.000381	0.00123	CcSEcCtD
Anagrelide—Arthralgia—Docetaxel—melanoma	0.000381	0.00123	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000379	0.00122	CcSEcCtD
Anagrelide—Dizziness—Carmustine—melanoma	0.000376	0.00121	CcSEcCtD
Anagrelide—Diarrhoea—Temozolomide—melanoma	0.000376	0.00121	CcSEcCtD
Anagrelide—Dry mouth—Docetaxel—melanoma	0.000373	0.0012	CcSEcCtD
Anagrelide—Confusional state—Docetaxel—melanoma	0.000368	0.00119	CcSEcCtD
Anagrelide—Oedema—Docetaxel—melanoma	0.000365	0.00118	CcSEcCtD
Anagrelide—Dizziness—Temozolomide—melanoma	0.000363	0.00117	CcSEcCtD
Anagrelide—Infection—Docetaxel—melanoma	0.000363	0.00117	CcSEcCtD
Anagrelide—Vomiting—Carmustine—melanoma	0.000362	0.00117	CcSEcCtD
Anagrelide—Nausea—Dactinomycin—melanoma	0.000361	0.00116	CcSEcCtD
Anagrelide—Shock—Docetaxel—melanoma	0.00036	0.00116	CcSEcCtD
Anagrelide—Rash—Carmustine—melanoma	0.000359	0.00116	CcSEcCtD
Anagrelide—Nervous system disorder—Docetaxel—melanoma	0.000358	0.00115	CcSEcCtD
Anagrelide—Dermatitis—Carmustine—melanoma	0.000358	0.00115	CcSEcCtD
Anagrelide—Thrombocytopenia—Docetaxel—melanoma	0.000358	0.00115	CcSEcCtD
Anagrelide—Tachycardia—Docetaxel—melanoma	0.000357	0.00115	CcSEcCtD
Anagrelide—Headache—Carmustine—melanoma	0.000356	0.00115	CcSEcCtD
Anagrelide—Skin disorder—Docetaxel—melanoma	0.000355	0.00114	CcSEcCtD
Anagrelide—Vomiting—Temozolomide—melanoma	0.000349	0.00113	CcSEcCtD
Anagrelide—Anorexia—Docetaxel—melanoma	0.000348	0.00112	CcSEcCtD
Anagrelide—Rash—Temozolomide—melanoma	0.000346	0.00112	CcSEcCtD
Anagrelide—Dermatitis—Temozolomide—melanoma	0.000346	0.00112	CcSEcCtD
Anagrelide—Headache—Temozolomide—melanoma	0.000344	0.00111	CcSEcCtD
Anagrelide—Hypotension—Docetaxel—melanoma	0.000341	0.0011	CcSEcCtD
Anagrelide—Nausea—Carmustine—melanoma	0.000338	0.00109	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Docetaxel—melanoma	0.000333	0.00107	CcSEcCtD
Anagrelide—Insomnia—Docetaxel—melanoma	0.00033	0.00107	CcSEcCtD
Anagrelide—Paraesthesia—Docetaxel—melanoma	0.000328	0.00106	CcSEcCtD
Anagrelide—Nausea—Temozolomide—melanoma	0.000326	0.00105	CcSEcCtD
Anagrelide—Dyspnoea—Docetaxel—melanoma	0.000326	0.00105	CcSEcCtD
Anagrelide—Somnolence—Docetaxel—melanoma	0.000325	0.00105	CcSEcCtD
Anagrelide—Dyspepsia—Docetaxel—melanoma	0.000322	0.00104	CcSEcCtD
Anagrelide—Decreased appetite—Docetaxel—melanoma	0.000318	0.00102	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Docetaxel—melanoma	0.000315	0.00102	CcSEcCtD
Anagrelide—Fatigue—Docetaxel—melanoma	0.000315	0.00102	CcSEcCtD
Anagrelide—Pain—Docetaxel—melanoma	0.000312	0.00101	CcSEcCtD
Anagrelide—Constipation—Docetaxel—melanoma	0.000312	0.00101	CcSEcCtD
Anagrelide—Feeling abnormal—Docetaxel—melanoma	0.000301	0.00097	CcSEcCtD
Anagrelide—Gastrointestinal pain—Docetaxel—melanoma	0.000299	0.000963	CcSEcCtD
Anagrelide—Body temperature increased—Docetaxel—melanoma	0.000289	0.000931	CcSEcCtD
Anagrelide—Abdominal pain—Docetaxel—melanoma	0.000289	0.000931	CcSEcCtD
Anagrelide—Asthenia—Docetaxel—melanoma	0.000262	0.000845	CcSEcCtD
Anagrelide—Pruritus—Docetaxel—melanoma	0.000259	0.000833	CcSEcCtD
Anagrelide—Diarrhoea—Docetaxel—melanoma	0.00025	0.000806	CcSEcCtD
Anagrelide—Dizziness—Docetaxel—melanoma	0.000242	0.000779	CcSEcCtD
Anagrelide—Vomiting—Docetaxel—melanoma	0.000232	0.000749	CcSEcCtD
Anagrelide—Rash—Docetaxel—melanoma	0.00023	0.000743	CcSEcCtD
Anagrelide—Dermatitis—Docetaxel—melanoma	0.00023	0.000742	CcSEcCtD
Anagrelide—Headache—Docetaxel—melanoma	0.000229	0.000738	CcSEcCtD
Anagrelide—Nausea—Docetaxel—melanoma	0.000217	0.0007	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—ITGAV—melanoma	7.7e-05	0.00395	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IFNA2—melanoma	7.52e-05	0.00385	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDK2—melanoma	7.49e-05	0.00384	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	7.36e-05	0.00377	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCR2—melanoma	7.29e-05	0.00374	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—RHOB—melanoma	7.27e-05	0.00373	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—RAC2—melanoma	7.17e-05	0.00368	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ITGB1—melanoma	6.99e-05	0.00358	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLCB4—melanoma	6.81e-05	0.00349	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL1—melanoma	6.81e-05	0.00349	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCR2—melanoma	6.62e-05	0.00339	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—RAC2—melanoma	6.51e-05	0.00334	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—WNT5A—melanoma	6.41e-05	0.00329	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TRRAP—melanoma	6.4e-05	0.00328	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CUL3—melanoma	6.4e-05	0.00328	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—HGF—melanoma	6.39e-05	0.00328	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—NFKB1—melanoma	6.35e-05	0.00326	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CSF2—melanoma	6.32e-05	0.00324	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKR1B10—melanoma	6.23e-05	0.00319	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—F2R—melanoma	6.2e-05	0.00318	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—melanoma	6.16e-05	0.00316	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ITGB3—melanoma	6.06e-05	0.00311	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PRKCA—melanoma	6.06e-05	0.00311	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—EDNRB—melanoma	6e-05	0.00308	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MAP2K1—melanoma	5.9e-05	0.00302	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ACER3—melanoma	5.85e-05	0.003	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—F2RL1—melanoma	5.79e-05	0.00297	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GAB2—melanoma	5.67e-05	0.00291	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GNA11—melanoma	5.67e-05	0.00291	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—F2R—melanoma	5.63e-05	0.00289	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—RAC1—melanoma	5.62e-05	0.00288	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDNRB—melanoma	5.45e-05	0.00279	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GRM3—melanoma	5.44e-05	0.00279	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MMP1—melanoma	5.44e-05	0.00279	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CDK2—melanoma	5.34e-05	0.00273	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCR4—melanoma	5.33e-05	0.00273	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	5.28e-05	0.00271	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GNAQ—melanoma	5.27e-05	0.0027	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—MDM2—melanoma	5.25e-05	0.00269	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KISS1—melanoma	5.16e-05	0.00265	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GAB2—melanoma	5.15e-05	0.00264	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GNA11—melanoma	5.15e-05	0.00264	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—melanoma	5.06e-05	0.00259	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SKI—melanoma	5e-05	0.00256	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCR1—melanoma	5e-05	0.00256	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—FN1—melanoma	4.96e-05	0.00254	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MC1R—melanoma	4.92e-05	0.00252	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS2—melanoma	4.9e-05	0.00251	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT3—melanoma	4.86e-05	0.00249	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCR4—melanoma	4.84e-05	0.00248	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	4.79e-05	0.00246	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—melanoma	4.79e-05	0.00246	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GNAQ—melanoma	4.79e-05	0.00245	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CG—melanoma	4.75e-05	0.00243	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—melanoma	4.74e-05	0.00243	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR7—melanoma	4.72e-05	0.00242	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GRM1—melanoma	4.72e-05	0.00242	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—EGF—melanoma	4.69e-05	0.0024	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	4.69e-05	0.0024	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP17A1—melanoma	4.65e-05	0.00238	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SUFU—melanoma	4.6e-05	0.00236	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP17A1—melanoma	4.58e-05	0.00235	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—melanoma	4.42e-05	0.00227	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT3—melanoma	4.42e-05	0.00226	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—melanoma	4.39e-05	0.00225	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF1—melanoma	4.35e-05	0.00223	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RHOB—melanoma	4.29e-05	0.0022	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BCL2L11—melanoma	4.29e-05	0.0022	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CD—melanoma	4.17e-05	0.00214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HDAC6—melanoma	4.13e-05	0.00211	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—melanoma	4.12e-05	0.00211	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—EDN1—melanoma	4.09e-05	0.00209	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CSF2—melanoma	3.99e-05	0.00205	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—melanoma	3.99e-05	0.00204	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—melanoma	3.94e-05	0.00202	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCR2—melanoma	3.91e-05	0.002	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1B1—melanoma	3.91e-05	0.002	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1B1—melanoma	3.86e-05	0.00198	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RAC2—melanoma	3.85e-05	0.00197	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PRKCA—melanoma	3.83e-05	0.00196	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—WNT5A—melanoma	3.79e-05	0.00194	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFC—melanoma	3.79e-05	0.00194	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDN1—melanoma	3.71e-05	0.0019	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—melanoma	3.67e-05	0.00188	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CB—melanoma	3.64e-05	0.00186	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CSF2—melanoma	3.63e-05	0.00186	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—melanoma	3.59e-05	0.00184	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	3.59e-05	0.00184	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—melanoma	3.59e-05	0.00184	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—RAC1—melanoma	3.55e-05	0.00182	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIP4K2A—melanoma	3.55e-05	0.00182	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PRKCA—melanoma	3.48e-05	0.00178	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—melanoma	3.42e-05	0.00175	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	3.42e-05	0.00175	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAP2K2—melanoma	3.4e-05	0.00174	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—melanoma	3.39e-05	0.00174	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IL2—melanoma	3.34e-05	0.00171	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—F2R—melanoma	3.33e-05	0.0017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—RAC1—melanoma	3.22e-05	0.00165	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDNRB—melanoma	3.22e-05	0.00165	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTK2B—melanoma	3.13e-05	0.0016	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNA11—melanoma	3.04e-05	0.00156	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GAB2—melanoma	3.04e-05	0.00156	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FLT1—melanoma	3.03e-05	0.00155	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CG—melanoma	3e-05	0.00154	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CUBN—melanoma	2.96e-05	0.00152	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—melanoma	2.88e-05	0.00148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCR4—melanoma	2.86e-05	0.00147	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FOXO4—melanoma	2.86e-05	0.00147	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HDAC2—melanoma	2.86e-05	0.00147	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—melanoma	2.84e-05	0.00146	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GNAQ—melanoma	2.83e-05	0.00145	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NRAS—melanoma	2.8e-05	0.00144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPAM—melanoma	2.77e-05	0.00142	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CG—melanoma	2.72e-05	0.0014	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MAPK3—melanoma	2.69e-05	0.00138	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SYK—melanoma	2.66e-05	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CD—melanoma	2.64e-05	0.00135	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGFR—melanoma	2.61e-05	0.00134	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT3—melanoma	2.61e-05	0.00134	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ITGAV—melanoma	2.61e-05	0.00134	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ACER3—melanoma	2.61e-05	0.00134	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MAPK1—melanoma	2.56e-05	0.00131	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SOCS1—melanoma	2.42e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—KRAS—melanoma	2.41e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAP2K1—melanoma	2.41e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—S100B—melanoma	2.41e-05	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CD—melanoma	2.39e-05	0.00123	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UGT2B10—melanoma	2.38e-05	0.00122	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	2.35e-05	0.00121	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB4—melanoma	2.31e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CB—melanoma	2.3e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN2B—melanoma	2.28e-05	0.00117	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—melanoma	2.22e-05	0.00114	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HS3ST5—melanoma	2.22e-05	0.00114	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CD86—melanoma	2.21e-05	0.00113	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—melanoma	2.21e-05	0.00113	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDN1—melanoma	2.19e-05	0.00112	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—melanoma	2.14e-05	0.0011	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CSF2—melanoma	2.14e-05	0.0011	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF1—melanoma	2.14e-05	0.0011	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL2—melanoma	2.11e-05	0.00108	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—E2F1—melanoma	2.1e-05	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CB—melanoma	2.09e-05	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDGFRA—melanoma	2.08e-05	0.00106	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCA—melanoma	2.05e-05	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ITGB3—melanoma	2.05e-05	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—HRAS—melanoma	2.05e-05	0.00105	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SPP1—melanoma	2.01e-05	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAP2K2—melanoma	2.01e-05	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—melanoma	2.01e-05	0.00103	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL2—melanoma	1.92e-05	0.000983	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TERT—melanoma	1.91e-05	0.000979	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RAC1—melanoma	1.9e-05	0.000976	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—melanoma	1.83e-05	0.000936	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—melanoma	1.81e-05	0.000928	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.78e-05	0.000914	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—melanoma	1.75e-05	0.000895	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FN1—melanoma	1.68e-05	0.000862	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCB4—melanoma	1.68e-05	0.000861	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—FASN—melanoma	1.65e-05	0.000845	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH1—melanoma	1.65e-05	0.000843	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CD80—melanoma	1.61e-05	0.000826	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APC—melanoma	1.61e-05	0.000825	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CG—melanoma	1.61e-05	0.000825	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KIT—melanoma	1.61e-05	0.000825	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—NRAS—melanoma	1.61e-05	0.000825	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGF—melanoma	1.59e-05	0.000815	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIP4K2A—melanoma	1.58e-05	0.00081	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC6A11—melanoma	1.58e-05	0.00081	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK3—melanoma	1.54e-05	0.00079	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTAP—melanoma	1.54e-05	0.000787	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BRAF—melanoma	1.51e-05	0.000775	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.5e-05	0.00077	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—melanoma	1.47e-05	0.000755	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK1—melanoma	1.47e-05	0.000752	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—melanoma	1.47e-05	0.000751	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAP2K1—melanoma	1.42e-05	0.00073	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CD—melanoma	1.41e-05	0.000725	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—melanoma	1.4e-05	0.000718	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KRAS—melanoma	1.39e-05	0.00071	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PHGDH—melanoma	1.37e-05	0.000702	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LUM—melanoma	1.37e-05	0.000702	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF2—melanoma	1.35e-05	0.000694	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HPSE—melanoma	1.34e-05	0.000688	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CUBN—melanoma	1.32e-05	0.000676	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SDHD—melanoma	1.27e-05	0.000653	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—BSG—melanoma	1.27e-05	0.000653	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CSPG4—melanoma	1.27e-05	0.000653	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—melanoma	1.27e-05	0.000652	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MDM2—melanoma	1.27e-05	0.00065	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ERBB2—melanoma	1.25e-05	0.00064	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CB—melanoma	1.23e-05	0.000632	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPAM—melanoma	1.23e-05	0.000632	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—melanoma	1.18e-05	0.000607	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HRAS—melanoma	1.18e-05	0.000603	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1B—melanoma	1.16e-05	0.000593	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—melanoma	1.14e-05	0.000587	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—melanoma	1.13e-05	0.000581	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL2—melanoma	1.13e-05	0.00058	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—melanoma	1.13e-05	0.000578	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—melanoma	1.1e-05	0.000566	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CTNNB1—melanoma	1.09e-05	0.00056	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—melanoma	1.07e-05	0.000549	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1A—melanoma	1.07e-05	0.000547	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTEN—melanoma	1.07e-05	0.000546	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NFKB1—melanoma	1.06e-05	0.000544	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLA2G6—melanoma	1.05e-05	0.000537	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—melanoma	1.04e-05	0.000533	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—melanoma	9.62e-06	0.000493	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT3—melanoma	9.53e-06	0.000488	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NRAS—melanoma	9.51e-06	0.000487	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—VCAN—melanoma	9.42e-06	0.000483	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK3—melanoma	9.1e-06	0.000467	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	8.91e-06	0.000457	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—melanoma	8.85e-06	0.000454	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK1—melanoma	8.66e-06	0.000444	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—melanoma	8.66e-06	0.000444	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	8.6e-06	0.000441	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KRAS—melanoma	8.18e-06	0.000419	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP17A1—melanoma	7.95e-06	0.000407	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	7.84e-06	0.000402	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	7.74e-06	0.000396	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—melanoma	7.52e-06	0.000385	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNA11—melanoma	7.5e-06	0.000385	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—FASN—melanoma	7.34e-06	0.000376	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—melanoma	7.27e-06	0.000373	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC5A5—melanoma	7.22e-06	0.00037	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNAQ—melanoma	6.98e-06	0.000358	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CD44—melanoma	6.98e-06	0.000358	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HRAS—melanoma	6.95e-06	0.000356	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.83e-06	0.00035	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.77e-06	0.000347	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1B1—melanoma	6.69e-06	0.000343	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—melanoma	6.66e-06	0.000341	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—melanoma	6.14e-06	0.000315	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.9e-06	0.000303	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCB1—melanoma	5.51e-06	0.000282	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PRKCA—melanoma	5.07e-06	0.00026	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ERCC2—melanoma	5.03e-06	0.000258	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.16e-06	0.000213	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CG—melanoma	3.97e-06	0.000203	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—melanoma	3.83e-06	0.000196	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CD—melanoma	3.49e-06	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—melanoma	3.45e-06	0.000177	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CB—melanoma	3.04e-06	0.000156	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—melanoma	3.01e-06	0.000154	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTEN—melanoma	2.63e-06	0.000135	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—melanoma	1.85e-06	9.5e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—melanoma	1.51e-06	7.76e-05	CbGpPWpGaD
